TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* - Informed consent obtained~* - Type 1 diabetes mellitus for 12 months or longer~* - Basal bolus or CSII (Continuous Subcutaneous Insulin Infusion, insulin pump) treatment for 6 months or longer~* - Stable insulin treatment for the last 3 months prior to Screening, as judged and documented by the investigator~* - HbA1c 7.0-10% (Diabetes Control and Complications Trial (DCCT)), both inclusive, (corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))~* - Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, complete trial related questionnaires, diaries, self-monitoring of plasma glucose, self titration of insulin and attend all scheduled visits~Exclusion Criteria:~* - Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPP-4) inhibitors~* - Use of any medication, which in the investigator's opinion could interfere with the glycaemic control or affect the subject's safety.Premix insulin is not allowed~* - Known proliferative retinopathy or maculopathy requiring acute treatment~* - Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator~* - Uncontrolled/ untreated blood pressure at screening above 160 mmHg for systolic or above 100 mmHg for diastolic~* - History of acute or chronic pancreatitis~* - Screening calcitonin value equal to or above 50 ng/L~* - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2)~* - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 0.6 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 1.2 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 1.8 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide placebo 0.6 mg + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 1.2 mg + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 1.8 mg + insulin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Galilei Lens Professional vs. Predicate Devices: a Comparison Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* spherical equivalent between -10 D and +10 D~* best-corrected VA of 20/100 or better.~Exclusion Criteria:~* strabism~* blepharitis~* nystagmus~* amblyopia~* anisometropia (spherical equivalent \> 1D)~* angle closure glaucoma~* seizure disorder~* brain damages~* Down syndrome~* trisomy 13 or 18~* cerebral palsy~* other serious disorders of the eye or central nervous systems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Normal (Type: EXPERIMENTAL): Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
- Mild Cataract (Type: ACTIVE_COMPARATOR): Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
- Severe cataract (Type: EXPERIMENTAL): Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.~Exclusion Criteria:~* Ductal carcinoma in situ (DCIS; stage 0 cancer),~* Advanced or distant metastatic stage,~* Receiving any neoadjuvant therapy,~* History of receiving any antibiotics within prior 3 months,~* History of immunodeficiency,~* Having a remote infection,~* History of reaction to study antibiotics,~* Denial of signing the consent form.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prophylaxis Group (Type: ACTIVE_COMPARATOR): patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
- No Prophylaxis Group (Type: NO_INTERVENTION): Patients who are BMI over 25 and do not receive antibiotic prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements~* Healthy males or females aged 18-65 inclusive and weighing ≥ 50 kg at the time of informed consent~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method~* BMI \< 35.0 kg/m2~* Subjects must have Lp(a) ≥ 75 nanomoles/liter nmol/L (30 mg/dL) at Screening~Exclusion Criteria:~* Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B~* Treatment with another Study Drug, biological agent, or device within one-month of screening~* Regular use of alcohol within 6 months of Screening~* Use of concomitant drugs unless authorized by the Sponsor Medical Monitor~* Smoking \> 10 cigarettes a day~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- IONIS-APO(a)-LRx (Type: EXPERIMENTAL): Drug: IONIS-APO(a)-LRx
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Drug: Sterile Normal Saline (0.9% NaCl)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Availability of written Informed Consent to participate in the study from the subject.~2. Male or female between 18 and 45 years old without previous contact with hepatitis B virus (HBV).~3. Good health condition based on full physical examination.~4. Normal values of laboratory biochemical blood tests.~5. Seronegative with respect to anti-HBs (surface) antibodies, anti-HBc (core) antibodies, and HBs Antigen (HBsAg) on screening.~6. Not pregnant and not breast-feeding.~7. For men and women of reproductive age: consent for use of an effective contraception method, for example, an intrauterine device, oral contraceptive, hypodermic implant or double barrier method (a condom with contraceptive sponge or contraceptive suppository) throughout the entire study.~Exclusion Criteria:~1. Congenital or inherited immunodeficiency disorder in family history.~2. Information of a serious blood disorder, cardiac disorder, or tumour.~3. Current use of any medication that could alter immune reactivity.~4. Infection with HBV at the present time or in the past, confirmed by HBV markers test.~5. Anaphylaxis or severe allergy, or atopy, history of alcoholism or drug abuse.~6. Pregnancy and breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sci-B-Vac® (Type: EXPERIMENTAL): The 3-antigen HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
- Engerix-B® (Type: ACTIVE_COMPARATOR): The single-antigen HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Have best corrected visual acuity of 0.60 logMAR or better in each eye as measured using Early Treatment of Diabetic Retinopathy Study chart~Exclusion Criteria:~* Have a known allergy and/or sensitivity to the test article(s) or its components or any therapies associated with the trial~* Have active signs or symptoms of any clinically significant ocular disorder (other than refractive disorders)~* Have a known bleeding disorder or history of bleeding complications after surgical or dental procedures~* Take aspirin, or take any other blood thinners or anti-coagulants (e.g. warfarin) including prescription, over the counter, or homeopathic therapies~* Have undergone any ocular surgical intervention within 3 months prior to Visit 1 or anticipate having ocular surgery during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Azithromycin-30 minutes Post dose (Type: EXPERIMENTAL): None
- Azithromycin-2 hours post dose (Type: EXPERIMENTAL): None
- Azithromycin-12 hours post dose (Type: EXPERIMENTAL): None
- Azithromycin-24 hours post dose (Type: EXPERIMENTAL): None
- Moxifloxacin-30 minutes post dose (Type: EXPERIMENTAL): None
- Moxifloxacin-2 hours post dose (Type: EXPERIMENTAL): None
- Moxifloxacin-12 hours post dose (Type: EXPERIMENTAL): None
- Moxafloxacin-24 hours post dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing Involuntary Movements in Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of using a dopamine receptor antagonist for at least 3 months~* Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening~* Subjects with underlying psychiatric diagnosis are stable and have no change in psychoactive medications~* Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months~* History of being compliant with prescribed medications~* Able to swallow study drug whole~* Be in good general health and is expected to attend all study visits and complete study assessments~* Female subjects must not be pregnant and must agree to an acceptable method of contraception throughout the study~Exclusion Criteria:~* Currently receiving medication for the treatment of tardive dyskinesia~* Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias~* Have a serious untreated or undertreated psychiatric illness~* Have recent history or presence of violent behavior~* Have unstable or serious medical illness~* Have evidence of hepatic impairment~* Have evidence of renal impairment~* Have known allergy to any component of SD-809 or tetrabenazine~* Has participated in an investigational drug or device trial and received study drug or device within 30 days~* Have acknowledged use of illicit drugs~* Have a history of alcohol or substance abuse in the previous 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets taken twice daily for 12 weeks.
- SD-809 12 mg/day (Type: EXPERIMENTAL): SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
- SD-809 24 mg/day (Type: EXPERIMENTAL): SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
- SD-809 36 mg/day (Type: EXPERIMENTAL): SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Four to fifteen Grade 1/2 actinic keratosis lesions (AKs) on one upper extremity~Exclusion Criteria:~* Pregnancy~* grade 3 and/or atypical \>1cm AKs within Treatment Area~* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis~* lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area~* skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy~* Subject is immunosuppressed~* unsuccessful outcome from previous ALA-PDT therapy~* currently enrolled in an investigational drug or device study~* has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment~* known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)~* use of the following topical preparations on the extremity to be treated:~  * Keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment.~ * Cryotherapy within 2 weeks of initiation of treatment~ * Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks of initiation of treatment.~ * Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment.~* use of systemic retinoid therapy within 6 months of initiation of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALA (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of axial spondylarthritis (axSpA, either ankylosing spondylitis or non radiographic axial spondylarthritis) according to ASAS axSpA classification criteria~* patients with back pain for at least 3 months and age of onset less than 45 years~* Active axSpA as assessed by total BASDAI score of at least 4 at Baseline.~* Spinal pain numeric rating scale score of more than 4 at Baseline.~* inadequate response to or failure to respond to at least 2 different NSAIDs at the highest recommended dose for at least 4 weeks in total prior to randomization~Key Exclusion Criteria:~* Chest X-ray or MRI with evidence of ongoing infectious or malignant process~* Patients previously treated with any biological immunomodulating agents, except those targeting tumor necrosis factor alpha.~* Patients who have been exposed to more than one anti-tumor necrosis factor alpha agent.~* Active ongoing inflammatory diseases other than axial spondyloarthritis~* Other ongoing mechanical diseases affecting the spine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 150 mg (Group A) (Type: EXPERIMENTAL): Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
- Placebo (Group B) (Type: PLACEBO_COMPARATOR): Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
- Arm A1 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
- Arm A2 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
- Arm A3 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
- Arm B1 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
- Arm B2 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DISEASE CHARACTERISTICS (Meets all of the following criteria):~  * Patient undergoing allogeneic hematopoietic stem cell transplant (HSCT)~ * Caregiver: the person in the patient's life who is primarily responsible for care decisions, emotionally invested in the patient's care, provides instrumental care such as transportation, and available if randomized to the fPER group to participate in the majority of intervention sessions~* PATIENT CHARACTERISTICS:~  * Able to read and speak English~ * Has telephone access~* CAREGIVER CHARACTERISTICS:~  * Able to read and speak English~ * Willingness to use a Smartphone~ * No serious medical condition likely to influence cortisol assessment in their hair~ * Alcohol consumption limited to \< 2 drinks/day~ * At least 18 years of age~Exclusion Criteria:~* PRIOR CONCURRENT THERAPY:~  * No history of a psychiatric illness unrelated to the HSCT within the past 18 months~ * No steroid medications (caregiver)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Caregiver Self-Directed (Type: NO_INTERVENTION): Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
- Caregiver Intervention (Type: EXPERIMENTAL): Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary hypercholesterolemia~Exclusion Criteria:~* The subject not meet the specified LDL-C level

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Livalo 2mg, Ezetrol 10mg (Type: EXPERIMENTAL): Pitavastatin 2mg, Ezetimibe 10mg
- Livalo 2mg (Type: ACTIVE_COMPARATOR): Pitavastatin 2mg
- Livalo 4mg, Ezetrol 10mg (Type: EXPERIMENTAL): Pitavastatin 4mg, Ezetimibe 10mg
- Livalo 4mg (Type: ACTIVE_COMPARATOR): Pitavastatin 4mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 50 years~2. Newly diagnosed, active subfoveal choroid neovascularisation (CNV) lesion secondary to AMD in the study eye~3. BCVA of 20/40 to 20/200 in the study eye~4. Written informed consent form~Exclusion Criteria:~1. Any previous ITV anti-vascular endothelial growth factor (anti-VEGF) treatment to treat neovascular AMD in either eye~2. Presence of CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture or pathologic myopia~3. Any concurrent macular abnormality other than AMD in the study eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SB11 (Proposed ranibizumab biosimilar) (Type: EXPERIMENTAL): None
- Lucentis (ranibizumab) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete